18 Recruiting Triple Negative Breast Cancer Phase 1 Clinical Trials
Active phase 1 studies for triple negative breast cancer enrolling across the USA. Verify eligibility and contact site coordinators.
All Triple Negative Breast Cancer studiesPhase 1 Studies for Triple Negative Breast Cancer
Ribociclib and Bicalutamide in AR+ TNBC
📍 University of Illinois Cancer Center — Chicago, Illinois
View Study & Checklist ➔Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
📍 University of Illinois — Chicago, Illinois
View Study & Checklist ➔A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
📍 Cedars-Sinai Medical Center — Los Angeles, California
View Study & Checklist ➔Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔Breast Cancer PSMA PET
📍 University of Iowa Healthcare — Iowa City, Iowa
View Study & Checklist ➔A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
📍 California Research Institute — Los Angeles, California
View Study & Checklist ➔A Study of Tetrathiomolybdate (TM) Plus Capecitabine
📍 Indiana University Simon Cancer Center — Indianapolis, Indiana
View Study & Checklist ➔ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
📍 Emory University Winship Cancer Institute — Atlanta, Georgia
View Study & Checklist ➔A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
📍 Mayo Clinic Comprehensive Cancer Center — Phoenix, Arizona
View Study & Checklist ➔A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
📍 Dren Investigational Site — Denver, Colorado
View Study & Checklist ➔Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
📍 UAB — Birmingham, Alabama
View Study & Checklist ➔A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
📍 City of Hope — Duarte, California
View Study & Checklist ➔A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
📍 USC / Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
📍 University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
View Study & Checklist ➔A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
📍 Los Angeles Cancer Network (LACN) - Good Sam — Los Angeles, California
View Study & Checklist ➔